Prosecution Insights
Last updated: April 19, 2026

Merchant & Gould Regeneron

8 pending office actions • 2 clients

Portfolio Summary

8
Total Pending OAs
1
Final Rejections
7
Non-Final OAs

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Regeneron Pharmaceuticals, Inc. 4
Regeneron Pharmaceuticals, Inc. 4

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18680910 ANTI-NPR1 ANTIBODIES AND USES THEREOF Regeneron Pharmaceuticals, Inc. HOWARD, ZACHARY C 1674 Non-Final OA May 31, 2024
18584551 ANTI-ACVR1 ANTIBODIES AND USES THEREOF Regeneron Pharmaceuticals, Inc. DEBERRY, REGINA M 1647 Non-Final OA Feb 22, 2024
18495477 ANTI-ACVRI ANTIBODIES AND THEIR USE IN THE TREATMENT OF TRAUMA-INDUCED HETEROTOPIC OSSIFICATION Regeneron Pharmaceuticals, Inc. MELCHIOR, JAMES RYLAND 1644 Non-Final OA Oct 26, 2023
18482448 ANTI-PTCRA ANTIBODY-DRUG CONJUGATES AND USES THEREOF Regeneron Pharmaceuticals, Inc. HUYNH, PHUONG N 1641 Non-Final OA Oct 06, 2023
18472160 METHODS OF TREATING OBESITY, DIABETES, AND LIVER DYSFUNCTION Regeneron Pharmaceuticals, Inc. PRIEST, JESSICA MARIE 1642 Non-Final OA Sep 21, 2023
18462320 METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES Regeneron Pharmaceuticals, Inc. TAYLOR, LIA ELAN 1641 Non-Final OA Sep 06, 2023
18059315 ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF Regeneron Pharmaceuticals, Inc. MCCOLLUM, ANDREA K 1674 Non-Final OA Nov 28, 2022
18045588 ANTIBODIES TO HUMAN GDF8 Regeneron Pharmaceuticals, Inc. XIE, XIAOZHEN 1674 Final Rejection Oct 11, 2022

Managing Merchant & Gould Regeneron's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month